Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal Dosing Study in Fabry Disease
NCT00075244Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jan 2004
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of agalsidase alfa in Fabry disease (FD), sponsored by National Institute of Neurological Disorders and Stroke. Started Jan 2004; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00075244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00075244.